Contineum CEO sells 2,500 shares after option exercise
Rhea-AI Filing Summary
Contineum Therapeutics, Inc. (CTNM) reported that CEO and President Carmine N. Stengone exercised options to acquire 2,500 shares of Class A common stock on September 8, 2026 at an exercise price of $1.01 per share and sold 2,500 shares on the same day at a weighted average price of $16.4566 per share. The option was granted under Contineum Therapeutics’ 2012 Equity Incentive Plan, is fully vested, and after this exercise 274,430 option shares from this award remain outstanding. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,500 shares ($39K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Stengone Carmine N.
Role
CEO and President
Sold
2,500 shs ($41K)
Approx. gross sale proceeds
$41K
Approx. exercise cost
$3K
Approx. pre-tax spread
$39K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F3 | 2,500 | $0.00 | $0.00 |
| Exercise | Class A Common Stock F1 | 2,500 | $1.01 | $3K |
| Sale | Class A Common Stock F1, F2 | 2,500 | $16.4566 | $41K |
Holdings After Transaction:
Stock Option (right to buy) — 274,430 contracts (Direct);
Class A Common Stock — 17,217 shares (Direct)
Footnotes (3)
- F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.
Key Figures
Options exercised: 2,500 shares
Option exercise price: $1.01 per share
Shares sold: 2,500 shares
+5 more
8 metrics
Options exercised
2,500 shares
Class A common stock acquired by option exercise on September 8, 2026
Option exercise price
$1.01 per share
Exercise price for the 2,500 shares on September 8, 2026
Shares sold
2,500 shares
Class A common stock sold on September 8, 2026
Weighted average sale price
$16.4566 per share
Average for sales ranging from $16.29 to $16.59 on September 8, 2026
Sale price range
$16.29–$16.59 per share
Price range for the 2,500 shares sold on September 8, 2026
Remaining option shares from this award
274,430 shares
Options to buy Class A common stock remaining after exercise; option expires February 24, 2030
Option expiration date
February 24, 2030
Expiration of the option award under the 2012 Equity Incentive Plan
Rule 10b5-1 plan adoption date
September 23, 2025
Date the trading plan governing these transactions was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Equity Incentive Plan
3 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Equity Incentive Plan financial
"Options granted under the Issuer's 2012 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
FAQ
What insider transactions did CTNM’s CEO report on September 8, 2026?
Carmine N. Stengone reported exercising options for 2,500 shares of Class A common stock at $1.01 per share and selling 2,500 shares at a weighted average price of $16.4566 per share on September 8, 2026.
What was the exercise price of the CTNM stock options used in this Form 4?
The options were exercised to acquire 2,500 shares of Class A common stock at an exercise price of $1.01 per share. These options were granted under Contineum Therapeutics’ 2012 Equity Incentive Plan and are fully vested.
Were the CTNM insider transactions made under a Rule 10b5-1 trading plan?
Yes. The filing states that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
What equity plan covers the options exercised in this CTNM Form 4?
The options exercised for 2,500 shares of Class A common stock were granted under Contineum Therapeutics’ 2012 Equity Incentive Plan, and the filing notes that the option is fully vested.
AI-generated analysis. How Rhea-AI works. Not financial advice.
